- Home
- ABTS vs RNAZ Comparison
ABTS vs RNAZ Comparison
Compare ABTS & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- RNAZ
- Stock Information
- Founded
- ABTS 2010
- RNAZ 2016
- Country
- ABTS Hong Kong
- RNAZ United States
- Employees
- ABTS N/A
- RNAZ N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- RNAZ Health Care
- Exchange
- ABTS Nasdaq
- RNAZ Nasdaq
- Market Cap
- ABTS 8.9M
- RNAZ 8.7M
- IPO Year
- ABTS N/A
- RNAZ 2021
- Fundamental
- Price
- ABTS $6.11
- RNAZ $9.41
- Analyst Decision
- ABTS
- RNAZ Strong Buy
- Analyst Count
- ABTS 0
- RNAZ 1
- Target Price
- ABTS N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- ABTS 57.2K
- RNAZ 19.3K
- Earning Date
- ABTS 08-13-2025
- RNAZ 11-14-2025
- Dividend Yield
- ABTS N/A
- RNAZ N/A
- EPS Growth
- ABTS N/A
- RNAZ N/A
- EPS
- ABTS N/A
- RNAZ N/A
- Revenue
- ABTS $7,037,156.00
- RNAZ N/A
- Revenue This Year
- ABTS N/A
- RNAZ N/A
- Revenue Next Year
- ABTS N/A
- RNAZ N/A
- P/E Ratio
- ABTS N/A
- RNAZ N/A
- Revenue Growth
- ABTS 31.69
- RNAZ N/A
- 52 Week Low
- ABTS $1.35
- RNAZ $6.15
- 52 Week High
- ABTS $14.10
- RNAZ $468.44
- Technical
- Relative Strength Index (RSI)
- ABTS 44.85
- RNAZ 34.66
- Support Level
- ABTS $5.80
- RNAZ $8.41
- Resistance Level
- ABTS $6.61
- RNAZ $9.85
- Average True Range (ATR)
- ABTS 0.52
- RNAZ 0.69
- MACD
- ABTS -0.06
- RNAZ -0.24
- Stochastic Oscillator
- ABTS 28.18
- RNAZ 7.99
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.